Lymphoma Research and Clinical Trials

“We have very good outcomes for our patients and getting to shepherd a patient through that tough time to get to the better times beyond is really the ultimate reward.”

Leslie Popplewell, M.D., Hematologist

Getting treated for lymphoma at City of Hope means you are steps away from labs where new treatments for cancer are being developed every day. That proximity means you benefit from something unique in cancer care – “bench to bedside” treatment. Bench to bedside means innovative research we are conducting in our labs is moved quickly to the bedside to treat our patients. We are testing dozens of new therapies and combinations for lymphoma patients, developed and manufactured in City of Hope’s own on-campus labs.

City of Hope has a long history of specializing in lymphoma, which includes some of the most common (Hodgkin, diffuse large B cell, follicular and small lymphocytic lymphomas) and the rarest (T cell non-Hodgkin, marginal and mantle cell lymhoma, Burkitt’s and hairy cell lymphomas) of hematological malignancies.

Led by Director Larry Kwak, M.D., Ph.D., the Dr. Michael Friedman Professor in Translational Medicine, and Associate Director Robert W. Chen, M.D., the Toni Stephenson Lymphoma Center within the Hematologic Malignancies Research Institute is committed to eliminating this disease by developing immune-based, nontransplant therapies, many of which have already shown promise in City of Hope’s laboratories. Each year, hundreds of lymphoma patients are enrolled in clinical trials at City of Hope.

 

Active Clinical Trials

FDA-approved CAR T Cell Therapy for Non-Hodgkin Lymphoma

To date, the U.S. Food & Drug Administration (FDA) has approved two forms of CAR T cell therapy for patients with non-Hodgkin lymphoma. City of Hope is one of the only institutions in the United States to offer both FDA-approved commercial products, axicabtagene ciloleucel (commercial name Yescarta) and tisagenlecleucel (commercial name Kymriah).

For all CAR T Inquiries (patient, physician, clinical trials), call 833-310-CART (2278).

Relapsed/Refractory Follicular Lymphoma

NCT02778685: Principal Investigator Elizabeth Budde, M.D., Ph.D.,   is actively recruiting for a study, presented at the 2021 ASH Conference, on the benefits of bispecific antibody — mosunetuzumab — for patients facing relapsed/refractory follicular lymphoma.
 
Clinical Trials Icon

Patient Enrollment Qualifications

  • Females 18 years of age or older
  • Eastern Cooperative Oncology Group performance status of 0 or 1
  • Adequate hepatic, hematologic and renal function
 
 
 

Relapsed/Refractory Diffuse B Cell Lymphoma

NCT03012100Principal investigator  Alex Herrera, M.D.,   is now recruiting patients for a Phase 2 study on the potential benefits of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as an initial salvage therapy in treating patients with diffuse large B cell lymphoma that has relapsed or does not respond to treatment.
 
Clinical Trials Icon

Patient Enrollment Qualifications

  • 18 years of age or older
  • Histologically confirmed diagnosis of diffuse large B cell lymphoma
  • Eastern Cooperative Oncology Group ≤ 2
  • Considered eligible for high-dose chemotherapy followed by ASCT 
 
 

Relapsed Classical Hodgkin Lymphoma

NCT04305834: Principal investigator Alex Herrera, M.D., is actively recruiting for a study on the benefits of brentuximab vedotin and nivolumab in treating patients with classical Hodgkin lymphoma that has relapsed. 
 
Clinical Trials Icon

Patient Enrollment Qualifications

  • 18 years of age or older
  • Histologically confirmed diagnosis of classical Hodgkin lymphoma (excluding nodular lymphocyte predominant Hodgkin lymphoma)
  • Eastern Cooperative Oncology Group ≤ 2
 
 
To refer a patient to one of our clinical trials, please call 626-218-1133 or visit CityofHope.org/Clinical-Trials.